Breaking News, Collaborations & Alliances

Goodwin, OncoMax in MAb Pact

Covers cell line engineering and manufacturing

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Goodwin Biotechnology, Inc. (GBI) and OncoMax, LLC have signed agreement for cell line engineering and manufacturing of a monoclonal antibody expressed in a mammalian cell line. The monoclonal antibody will be engineered with GBI’s collaborative partner Rafagen, and GBI will then evaluate the cell lines, select the highest producer and manufacture the monoclonal antibody for use and evaluation in clinical trials as a potential treatment for renal cell carcinoma. “This is an exciting...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters